VMD vs. PNTG, AVAH, AGL, LFMD, FLGT, PSNL, CSTL, INNV, FTRE, and EHAB
Should you be buying Viemed Healthcare stock or one of its competitors? The main competitors of Viemed Healthcare include The Pennant Group (PNTG), Aveanna Healthcare (AVAH), Agilon Health (AGL), LifeMD (LFMD), Fulgent Genetics (FLGT), Personalis (PSNL), Castle Biosciences (CSTL), InnovAge (INNV), Fortrea (FTRE), and Enhabit (EHAB). These companies are all part of the "healthcare" industry.
Viemed Healthcare vs. Its Competitors
Viemed Healthcare (NASDAQ:VMD) and The Pennant Group (NASDAQ:PNTG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.
74.2% of Viemed Healthcare shares are owned by institutional investors. Comparatively, 85.9% of The Pennant Group shares are owned by institutional investors. 20.0% of Viemed Healthcare shares are owned by insiders. Comparatively, 5.4% of The Pennant Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Viemed Healthcare has a net margin of 5.28% compared to The Pennant Group's net margin of 3.40%. The Pennant Group's return on equity of 10.73% beat Viemed Healthcare's return on equity.
The Pennant Group has higher revenue and earnings than Viemed Healthcare. Viemed Healthcare is trading at a lower price-to-earnings ratio than The Pennant Group, indicating that it is currently the more affordable of the two stocks.
Viemed Healthcare has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, The Pennant Group has a beta of 1.51, meaning that its share price is 51% more volatile than the S&P 500.
In the previous week, Viemed Healthcare had 1 more articles in the media than The Pennant Group. MarketBeat recorded 6 mentions for Viemed Healthcare and 5 mentions for The Pennant Group. The Pennant Group's average media sentiment score of 0.81 beat Viemed Healthcare's score of 0.32 indicating that The Pennant Group is being referred to more favorably in the news media.
The Pennant Group has a consensus price target of $34.60, indicating a potential upside of 31.58%. Given The Pennant Group's stronger consensus rating and higher possible upside, analysts clearly believe The Pennant Group is more favorable than Viemed Healthcare.
Summary
The Pennant Group beats Viemed Healthcare on 12 of the 16 factors compared between the two stocks.
Get Viemed Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for VMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viemed Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:VMD) was last updated on 7/4/2025 by MarketBeat.com Staff
Free VMD Stock Alerts